$ACRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACELRX PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACELRX PHARMACEUTICALS INC. Get notifications about new insider transactions in ACELRX PHARMACEUTICALS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 2021 | ACRX | ACELRX PHARMACEUTI ... | Bozilenko Marina | Director | Option Exercise | A | 1.61 | 30,000 | 48,300 | 30,000 | |
| Mar 31 2021 | ACRX | ACELRX PHARMACEUTI ... | Bozilenko Marina | Director | Grant | A | 0.00 | 15,000 | 0 | 15,000 | 0 to 15 K |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 1.88 | 68,750 | 129,250 | 68,750 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 1.88 | 137,500 | 258,500 | 137,500 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Grant | A | 0.00 | 68,750 | 0 | 666,621 | 597.9 K to 666.6 K (+11.50 %) |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 1.88 | 50,000 | 94,000 | 50,000 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 1.88 | 100,000 | 188,000 | 100,000 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Grant | A | 0.00 | 50,000 | 0 | 204,757 | 154.8 K to 204.8 K (+32.31 %) |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 1.88 | 68,750 | 129,250 | 68,750 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 1.88 | 137,500 | 258,500 | 137,500 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 0.00 | 68,750 | 0 | 260,597 | 191.8 K to 260.6 K (+35.84 %) |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Option Exercise | A | 1.88 | 1,000,000 | 1,880,000 | 1,000,000 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Grant | A | 0.00 | 200,000 | 0 | 636,980 | 437 K to 637 K (+45.77 %) |
| Feb 12 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Payment of Exercise | F | 2.63 | 9,024 | 23,733 | 183,299 | 192.3 K to 183.3 K (-4.69 %) |
| Feb 12 2021 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Payment of Exercise | F | 2.63 | 6,775 | 17,818 | 144,757 | 151.5 K to 144.8 K (-4.47 %) |
| Feb 12 2021 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Payment of Exercise | F | 2.63 | 8,915 | 23,446 | 593,098 | 602 K to 593.1 K (-1.48 %) |
| Feb 12 2021 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Payment of Exercise | F | 2.63 | 23,052 | 60,627 | 427,887 | 450.9 K to 427.9 K (-5.11 %) |
| Feb 09 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Payment of Exercise | F | 2.59 | 9,414 | 24,382 | 192,323 | 201.7 K to 192.3 K (-4.67 %) |
| Feb 09 2021 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Payment of Exercise | F | 2.59 | 6,846 | 17,731 | 151,532 | 158.4 K to 151.5 K (-4.32 %) |
| Feb 09 2021 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Payment of Exercise | F | 2.59 | 25,059 | 64,903 | 450,939 | 476 K to 450.9 K (-5.26 %) |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | Afable Richard | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | Afable Richard | Director | Grant | A | 0.00 | 7,500 | 0 | 12,250 | 4.8 K to 12.3 K (+157.89 %) |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Grant | A | 0.00 | 7,500 | 0 | 251,250 | 243.8 K to 251.3 K (+3.08 %) |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | HOFFMAN STEPHEN J | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | HOFFMAN STEPHEN J | Director | Grant | A | 0.00 | 7,500 | 0 | 11,250 | 3.8 K to 11.3 K (+200.00 %) |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | Rosen Howard B | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | Rosen Howard B | Director | Grant | A | 0.00 | 7,500 | 0 | 68,750 | 61.3 K to 68.8 K (+12.24 %) |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Grant | A | 0.00 | 7,500 | 0 | 186,250 | 178.8 K to 186.3 K (+4.20 %) |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
| Jun 16 2020 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Grant | A | 0.00 | 7,500 | 0 | 11,250 | 3.8 K to 11.3 K (+200.00 %) |
| Jun 15 2020 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Sell | P | 1.29 | 100,000 | 128,900 | 178,750 | 278.8 K to 178.8 K (-35.87 %) |
| Jun 15 2020 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Buy | P | 1.33 | 7,547 | 10,035 | 468,757 | 461.2 K to 468.8 K (+1.64 %) |
| Feb 13 2020 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Payment of Exercise | F | 1.71 | 7,924 | 13,550 | 188,765 | 196.7 K to 188.8 K (-4.03 %) |
| Feb 13 2020 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Payment of Exercise | F | 1.71 | 23,052 | 39,419 | 452,892 | 475.9 K to 452.9 K (-4.84 %) |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 1.72 | 137,500 | 236,500 | 137,500 | |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Grant | A | 0.00 | 68,750 | 0 | 612,907 | 544.2 K to 612.9 K (+12.63 %) |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 1.72 | 100,000 | 172,000 | 100,000 | |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Grant | A | 0.00 | 50,000 | 0 | 163,267 | 113.3 K to 163.3 K (+44.14 %) |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Option Exercise | A | 1.72 | 400,000 | 688,000 | 400,000 | |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Grant | A | 0.00 | 200,000 | 0 | 475,944 | 275.9 K to 475.9 K (+72.48 %) |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 1.72 | 137,500 | 236,500 | 137,500 | |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 0.00 | 68,750 | 0 | 196,689 | 127.9 K to 196.7 K (+53.74 %) |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 1.72 | 100,000 | 172,000 | 100,000 | |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 0.00 | 50,000 | 0 | 133,382 | 83.4 K to 133.4 K (+59.96 %) |
| Nov 12 2019 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 1.78 | 25,000 | 44,575 | 243,750 | 218.8 K to 243.8 K (+11.43 %) |
| Nov 12 2019 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Buy | P | 1.79 | 8,379 | 14,973 | 275,944 | 267.6 K to 275.9 K (+3.13 %) |
| Nov 04 2019 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 2.23 | 47,575 | 105,854 | 95,150 | |
| Nov 04 2019 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 2.23 | 31,625 | 70,366 | 63,250 | |
| Nov 04 2019 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.23 | 26,125 | 58,128 | 52,250 | |
| Nov 04 2019 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.23 | 40,563 | 90,253 | 81,125 | |
| Nov 04 2019 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Option Exercise | A | 2.23 | 96,250 | 214,156 | 192,500 | |
| Aug 26 2019 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.17 | 5,000 | 10,850 | 218,750 | 213.8 K to 218.8 K (+2.34 %) |
| Aug 26 2019 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.20 | 10,000 | 21,956 | 213,750 | 203.8 K to 213.8 K (+4.91 %) |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | A | 2.19 | 7,500 | 16,425 | 7,500 | |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Grant | A | 0.00 | 3,750 | 0 | 3,750 | 0 to 3.8 K |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | Rosen Howard B | Director | Option Exercise | A | 2.19 | 7,500 | 16,425 | 7,500 | |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | Rosen Howard B | Director | Grant | A | 0.00 | 3,750 | 0 | 61,250 | 57.5 K to 61.3 K (+6.52 %) |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | HOFFMAN STEPHEN J | Director | Option Exercise | A | 2.19 | 7,500 | 16,425 | 7,500 | |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | HOFFMAN STEPHEN J | Director | Grant | A | 0.00 | 3,750 | 0 | 3,750 | 0 to 3.8 K |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | Afable Richard | Director | Option Exercise | A | 2.19 | 7,500 | 16,425 | 7,500 | |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | Afable Richard | Director | Grant | A | 0.00 | 3,750 | 0 | 4,750 | 1,000 to 4.8 K (+375.00 %) |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Option Exercise | A | 2.19 | 7,500 | 16,425 | 7,500 | |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Grant | A | 0.00 | 3,750 | 0 | 78,750 | 75 K to 78.8 K (+5.00 %) |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Option Exercise | A | 2.19 | 7,500 | 16,425 | 7,500 | |
| Jun 25 2019 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Grant | A | 0.00 | 3,750 | 0 | 203,750 | 200 K to 203.8 K (+1.88 %) |
| Jun 06 2019 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Buy | P | 2.31 | 5,000 | 11,550 | 262,884 | 257.9 K to 262.9 K (+1.94 %) |
| Mar 12 2019 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.99 | 19,000 | 56,890 | 200,000 | 181 K to 200 K (+10.50 %) |
| Mar 04 2019 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 2.81 | 3,647 | 10,248 | 124,397 | 120.8 K to 124.4 K (+3.02 %) |
| Mar 04 2019 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Buy | P | 2.81 | 9,206 | 25,869 | 113,267 | 104.1 K to 113.3 K (+8.85 %) |
| Mar 04 2019 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Buy | P | 2.81 | 3,234 | 9,088 | 257,884 | 254.7 K to 257.9 K (+1.27 %) |
| Mar 04 2019 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Buy | P | 2.81 | 840 | 2,360 | 541,724 | 540.9 K to 541.7 K (+0.16 %) |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.51 | 100,000 | 251,000 | 100,000 | |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 0.00 | 50,000 | 0 | 74,371 | 24.4 K to 74.4 K (+205.16 %) |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 2.51 | 100,000 | 251,000 | 100,000 | |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Grant | A | 0.00 | 50,000 | 0 | 104,061 | 54.1 K to 104.1 K (+92.49 %) |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.51 | 137,500 | 345,125 | 137,500 | |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 0.00 | 68,750 | 0 | 120,750 | 52 K to 120.8 K (+132.21 %) |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 2.51 | 137,500 | 345,125 | 137,500 | |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Grant | A | 0.00 | 68,750 | 0 | 540,884 | 472.1 K to 540.9 K (+14.56 %) |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Option Exercise | A | 2.51 | 400,000 | 1,004,000 | 400,000 | |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Grant | A | 0.00 | 200,000 | 0 | 254,650 | 54.7 K to 254.7 K (+365.97 %) |
| Dec 17 2018 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Buy | P | 2.78 | 3,610 | 10,024 | 54,650 | 51 K to 54.7 K (+7.07 %) |
| Dec 17 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 2.78 | 5,000 | 13,883 | 52,000 | 47 K to 52 K (+10.64 %) |
| Dec 12 2018 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Buy | P | 2.99 | 10,000 | 29,890 | 51,040 | 41 K to 51 K (+24.37 %) |
| Nov 19 2018 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Buy | P | 3.07 | 16,000 | 49,120 | 472,134 | 456.1 K to 472.1 K (+3.51 %) |
| Nov 15 2018 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.82 | 20,700 | 58,376 | 181,000 | 160.3 K to 181 K (+12.91 %) |
| Nov 13 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 3.13 | 5,000 | 15,646 | 47,000 | 42 K to 47 K (+11.90 %) |
| Nov 13 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 3.13 | 5,000 | 15,646 | 47,000 | 42 K to 47 K (+11.90 %) |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | D | 2.23 | 5,000 | 11,125 | 21,125 | |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.23 | 26,125 | 58,128 | 26,125 | |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Sell | D | 5.00 | 5,000 | 25,000 | 29,795 | 34.8 K to 29.8 K (-14.37 %) |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 2.23 | 5,000 | 11,125 | 34,795 | 29.8 K to 34.8 K (+16.78 %) |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 2.23 | 31,625 | 70,366 | 31,625 | |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.23 | 40,562 | 90,250 | 40,562 | |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 2.23 | 47,575 | 105,854 | 47,575 | |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Option Exercise | A | 2.23 | 96,250 | 214,156 | 96,250 | |
| Oct 16 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Sell | S | 5.00 | 5,216 | 26,080 | 29,795 | 35 K to 29.8 K (-14.90 %) |
| Oct 16 2018 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Sell | S | 5.00 | 28,351 | 141,755 | 54,061 | 82.4 K to 54.1 K (-34.40 %) |
| Sep 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Sell | S | 4.50 | 6,953 | 31,289 | 35,011 | 42 K to 35 K (-16.57 %) |
| Sep 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Grant | A | 1.49 | 8,022 | 11,953 | 82,412 | 74.4 K to 82.4 K (+10.78 %) |
| Sep 05 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 1.49 | 10,000 | 14,900 | 42,000 | 32 K to 42 K (+31.25 %) |
| Sep 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Grant | A | 1.49 | 6,040 | 9,000 | 41,040 | 35 K to 41 K (+17.26 %) |
| Sep 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 1.49 | 6,876 | 10,245 | 24,371 | 17.5 K to 24.4 K (+39.30 %) |
| Aug 08 2018 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.84 | 5,300 | 15,063 | 160,300 | 155 K to 160.3 K (+3.42 %) |
| Aug 08 2018 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.84 | 5,300 | 15,063 | 160,300 | 155 K to 160.3 K (+3.42 %) |
| Aug 07 2018 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Buy | P | 2.90 | 10,000 | 28,950 | 35,000 | 25 K to 35 K (+40.00 %) |
| Aug 06 2018 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Buy | P | 2.75 | 37,000 | 101,750 | 456,134 | 419.1 K to 456.1 K (+8.83 %) |
| Aug 06 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 2.75 | 5,000 | 13,725 | 32,000 | 27 K to 32 K (+18.52 %) |
| Jun 14 2018 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Option Exercise | A | 4.13 | 15,000 | 61,875 | 15,000 | |
| Jun 14 2018 | ACRX | ACELRX PHARMACEUTI ... | Afable Richard | Director | Option Exercise | A | 4.13 | 15,000 | 61,875 | 15,000 | |
| Jun 14 2018 | ACRX | ACELRX PHARMACEUTI ... | HOFFMAN C STEVEN | Director | Option Exercise | A | 4.13 | 15,000 | 61,875 | 15,000 | |
| Jun 14 2018 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Option Exercise | A | 4.13 | 15,000 | 61,875 | 15,000 | |
| Jun 14 2018 | ACRX | ACELRX PHARMACEUTI ... | Rosen Howard B | Director | Option Exercise | A | 4.13 | 15,000 | 61,875 | 15,000 | |
| Jun 14 2018 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | A | 4.13 | 15,000 | 61,875 | 15,000 | |
| Jun 05 2018 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 3.35 | 4,700 | 15,745 | 155,000 | 150.3 K to 155 K (+3.13 %) |
| Jun 05 2018 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 3.30 | 300 | 990 | 150,300 | 150 K to 150.3 K (+0.20 %) |
| May 29 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 3.18 | 5,000 | 15,923 | 27,000 | 22 K to 27 K (+22.73 %) |
| May 23 2018 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Sell | J | 0.00 | 126,153 | 0 | 0 | 126.2 K to 0 (-100.00 %) |
| May 23 2018 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Sell | J | 0.00 | 5,713,569 | 0 | 0 | 5.7 M to 0 (-100.00 %) |
| May 23 2018 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Sell | J | 0.00 | 179,962 | 0 | 0 | 180 K to 0 (-100.00 %) |
| May 23 2018 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Sell | J | 0.00 | 3,347,357 | 0 | 0 | 3.3 M to 0 (-100.00 %) |
| Apr 18 2018 | ACRX | ACELRX PHARMACEUTI ... | Saia John G. | General Counsel and ... | Option Exercise | A | 2.40 | 145,000 | 348,000 | 145,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.00 | 147,500 | 295,000 | 147,500 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 2.00 | 115,000 | 230,000 | 115,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.00 | 95,000 | 190,000 | 95,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 2.00 | 173,000 | 346,000 | 173,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Option Exercise | A | 2.00 | 350,000 | 700,000 | 350,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.00 | 147,500 | 295,000 | 147,500 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 2.00 | 115,000 | 230,000 | 115,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.00 | 95,000 | 190,000 | 95,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 2.00 | 173,000 | 346,000 | 173,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Option Exercise | A | 2.00 | 350,000 | 700,000 | 350,000 | |
| Nov 15 2017 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 1.90 | 30,000 | 56,970 | 150,000 | 120 K to 150 K (+25.00 %) |
| Nov 14 2017 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 1.94 | 5,000 | 9,711 | 12,000 | 7 K to 12 K (+71.43 %) |
| Oct 20 2017 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | M | 1.20 | 37,500 | 45,000 | 0 | |
| Oct 20 2017 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Buy | M | 1.20 | 37,500 | 45,000 | 74,390 | 36.9 K to 74.4 K (+101.65 %) |
| Sep 27 2017 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Sell | S | 0.00 | 13,827 | 0 | 68,504 | 82.3 K to 68.5 K (-16.79 %) |
| Sep 11 2017 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 3.24 | 7,000 | 22,705 | 7,000 | 0 to 7 K |
| Aug 24 2017 | ACRX | ACELRX PHARMACEUTI ... | Angotti Vincent J. | Chief Executive Off ... | Buy | P | 3.00 | 15,000 | 45,000 | 15,000 | 0 to 15 K |
| Aug 24 2017 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 3.03 | 4,800 | 14,520 | 120,000 | 115.2 K to 120 K (+4.17 %) |
| Aug 24 2017 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.90 | 200 | 580 | 115,200 | 115 K to 115.2 K (+0.17 %) |
| Aug 22 2017 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Buy | P | 2.95 | 10,000 | 29,487 | 415,801 | 405.8 K to 415.8 K (+2.46 %) |
| Aug 17 2017 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 3.00 | 220,000 | 660,000 | 220,000 | |
| Jun 21 2017 | ACRX | ACELRX PHARMACEUTI ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Sell | S | 2.40 | 875,000 | 2,100,000 | 4,533,728 | 5.4 M to 4.5 M (-16.18 %) |
| Jun 15 2017 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Option Exercise | A | 2.30 | 15,000 | 34,500 | 15,000 | |
| Jun 15 2017 | ACRX | ACELRX PHARMACEUTI ... | HOFFMAN C STEVEN | Director | Option Exercise | A | 2.30 | 15,000 | 34,500 | 15,000 | |
| Jun 15 2017 | ACRX | ACELRX PHARMACEUTI ... | Rosen Howard B | Director | Option Exercise | A | 2.30 | 15,000 | 34,500 | 15,000 | |
| Jun 15 2017 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | A | 2.30 | 15,000 | 34,500 | 15,000 |